lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
The psi-loop (Ψ-loop) motif consists of two antiparallel strands with one strand in between that is connected to both by hydrogen bonds. There are four possible strand topologies for single Ψ-loops. This motif is rare as the process resulting in its formation seems unlikely to occur during protein folding. The Ψ-loop was first identified in the aspartic protease family. β-sheets are present in all-β, α+β and α/β domains, and in many peptides or small proteins with poorly defined overall architecture. All-β domains may form β-barrels, β-sandwiches, β-prisms, β-propellers, and β-helices.
In October 2006, researchers announced that three atoms of oganesson (element 118) had been identified at Joint Institute for Nuclear Research in Dubna, Russia, from bombarding 249Cf with calcium-48, making it the heaviest element ever made. The target contained about 10 mg of 249Cf deposited on a titanium foil of 32 cm2 area. Californium has also been used to produce other transuranic elements; for example, lawrencium was first synthesized in 1961 by bombarding californium with boron nuclei.
== Toxicity == Highly charged and heavy, alpha particles lose their several MeV of energy within a small volume of material, along with a very short mean free path. This increases the chance of double-strand breaks to the DNA in cases of internal contamination, when ingested, inhaled, injected or introduced through the skin. Otherwise, touching an alpha source is typically not harmful, as alpha particles are effectively shielded by a few centimeters of air, a piece of paper, or the thin layer of dead skin cells that make up the epidermis; however, the decay chain of many alpha emitting isotopes, for example Radium 226, contain daughter nuclei that undergo beta- and/or gamma-decay. Relative biological effectiveness (RBE) quantifies the ability of radiation to cause certain biological effects, notably either cancer or cell-death, for equivalent radiation exposure. Alpha radiation has a high linear energy transfer (LET) coefficient, which is about one ionization of a molecule/atom for every angstrom of travel by the alpha particle. The RBE has been set at the value of 20 for alpha radiation by various government regulations. The RBE is set at 10 for neutron irradiation, and at 1 for beta radiation and ionizing photons. However, the recoil of the parent nucleus (alpha recoil) gives it a significant amount of energy, which also causes ionization damage (see ionizing radiation). This energy is roughly the weight of the alpha (4 Da) divided by the weight of the parent (typically about 200 Da) times the total energy of the alpha.
No. 237 Squadron, based in Kenya since before the start of the war, had expanded to 28 officers and 209 other ranks by March 1940. By mid-1940, most of the officers and men Southern Rhodesia had sent overseas were in Kenya, attached to various East African formations, the King's African Rifles (KAR), the RWAFF, or to the colony's own Medical Corps or Survey Unit. The Southern Rhodesian surveyors charted the previously unmapped area bordering Abyssinia and Italian Somaliland between March and June 1940, and the Medical Corps operated No. 2 General Hospital in Nairobi from July. A company of coloured and Indian-Rhodesian transport drivers was also in the country, having arrived in January. The first Southern Rhodesian contingent despatched to North Africa and the Middle East was a draft of 700 from the Rhodesia Regiment who left in April 1940. No white Rhodesian force of this size had ever left the territory before. They were posted to a variety of British units across Egypt and Palestine. The largest concentration of Rhodesian soldiers in North Africa belonged to the King's Royal Rifle Corps (KRRC), whose connections with the colony dated back to World War I. Several Rhodesian platoons were formed in the KRRC's 1st Battalion in the Western Desert. A company of men from the Southern Rhodesian Signal Corps was also present, operating in tandem with the British Royal Corps of Signals.
Sources: en.wikipedia.org
In 2023, it was the 246th most commonly prescribed medication in the United States, with more than 1 million prescriptions. It is available as a generic medication. In 2023, the combination of dexamethasone with neomycin and polymyxin B was the 260th most commonly prescribed medication in the United States, with more than 1 million prescriptions; and the combination of dexamethasone with ciprofloxacin was the 283rd most commonly prescribed medication in the United States, with more than 700,000 prescriptions;
== Biosynthesis == Five enzymes participate in the parallel synthesis pathways for isoleucine, valine, and leucine: threonine dehydrogenase, acetohydroxyacid synthase, ketol-acid reductoisomerase, dihydroxyacid dehydrogenase and aminotransferase. Threonine dehydrogenase catalyzes the deamination and dehydration of threonine to 2-ketobutyrate and ammonia. Isoleucine forms a negative feedback loop with threonine dehydrogenase. Acetohydroxyacid synthase is the first enzyme for the parallel pathway performing condensation reaction in both steps – condensation of pyruvate to acetolactate in the valine pathway and condensation of pyruvate and 2-ketobutyrate to form acetohydroxybutyrate in the isoleucine pathway. Next ketoacid reductoisomerase reduces the acetohydroxy acids from the previous step to yield dihydroxyacids in both the valine and isoleucine pathways. Dihydroxyacid dehydrogenase converts the dihyroxyacids in the next step. The final step in the parallel pathway is conducted by amino transferase, which yields the final products of valine and isoleucine. A series of four more enzymes – 2-isopropylmalate synthase, isopropylmalate isomerase, isopropylmalate dehydrogenase, and aminotransferase – are necessary for the formation of leucine from 2-oxolsovalerate.
Medicare was established in 1965 and expanded thereafter. Spending for Medicare during 2016 was $692 billion, versus $634 billion in 2014, an increase of $58 billion or 9%. In 2013, the program covered an estimated 52.3 million persons. It consists of four distinct parts which are funded differently: Hospital Insurance, mainly funded by a dedicated payroll tax of 2.9% of earnings, shared equally between employers and workers; Supplementary Medical Insurance, funded through beneficiary premiums (set at 25% of estimated program costs for the aged) and general revenues (the remaining amount, approximately 75%); Medicare Advantage, a private plan option for beneficiaries, funded through the Hospital Insurance and Supplementary Medical Insurance trust funds; and the Part D prescription drug benefits, for which funding is included in the Supplementary Medical Insurance trust fund and is financed through beneficiary premiums (about 25%) and general revenues (about 75%). Spending on Medicare and Medicaid is projected to grow dramatically in coming decades. The number of persons enrolled in Medicare is expected to increase from 47 million in 2010 to 80 million by 2030. While the same demographic trends that affect Social Security also affect Medicare, rapidly rising medical prices appear to be a more important cause of projected spending increases. CBO expects Medicare and Medicaid to continue growing, rising from 5.3% GDP in 2009 to 10.0% in 2035 and 19.0% by 2082. CBO has indicated healthcare spending per beneficiary is the primary long-term fiscal challenge.
Sources: en.wikipedia.org
== External links == Adrenomedullin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human ADM genome location and ADM gene details page in the UCSC Genome Browser. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Post-translational modification (PTM) isoforms are easily detected on 2D gels. Indeed, phosphorylation replaces neutral hydroxyl groups on serines, threonines, or tyrosines with negatively charged phosphates with pKs near 1.2 and 6.5. Thus, below pH 5.5, phosphates add a single negative charge; near pH 6.5, they add 1.5 negative charges; above pH 7.5, they add 2 negative charges. The relative amount of each isoform can also easily and rapidly be determined from staining intensity on 2D gels. In some very specific cases, the detection of the phosphorylation as a shift in the protein's electrophoretic mobility is possible on simple 1-dimensional SDS-PAGE gels, as it is described for instance for a transcriptional coactivator by Kovacs et al. Strong phosphorylation-related conformational changes (that persist in detergent-containing solutions) are thought to underlie this phenomenon. Most of the phosphorylation sites for which such a mobility shift has been described fall in the category of SP and TP sites (i.e. a proline residue follows the phosphorylated serine or threonine residue). Large-scale mass spectrometry analyses have been used to determine sites of protein phosphorylation. Dozens of studies have been published, each identifying thousands of sites, many of which were previously undescribed. Mass spectrometry is ideally suited for such analyses using HCD or ETD fragmentation, as the addition of phosphorylation results in an increase in the mass of the protein and the phosphorylated residue.
==== Toronto City Council ==== The Ford government passed the Better Local Government Act into law on August 14, 2018. Premier Ford announced the controversial bill on September 27, on the last day for candidate registration for the October 22, 2018 Toronto municipal election, newly elected Premier of Ontario Doug Ford introduced the Better Local Government Act (Bill 5) which requires that Toronto use the same ridings for all its elections—municipal, provincial, and federal—effectively reducing the Toronto City Council from 47 seats to 25. Bill 5 passed on August 14, 2018. Toronto is Ontario's capital city and the largest city in Canada with a population of 2.7 million. The number of Council seats had just been expanded following approximately four years of consultations and debates. Ford said that these reductions would lower the cost to taxpayers by $CDN 25 ($USD19.1) million dollars in Toronto's $CDN11.1 ($USD8.5) billion dollar budget. Bill 5 reset the positions of regional municipality chairs as by appointment not be election in Peel, York, Niagara and Muskoka.
== East Africa == Its East Africa, laboratories include Pathologists Lancet Kenya Limited, established in 2009. Others include Lancet Laboratories Uganda Limited and Lancet Laboratories Tanzania Limited.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.